United States Patent 7,989,474: Nintedanib Lung-Fibrosis Patent Scope and Competitive Landscape

U.S. Patent 7,989,474 protects the use of nintedanib, also known as BIBF 1120, for treating lung fibrosis. Its core protection is a method-of-treatment claim directed to administering nintedanib, or a defined pharmaceutical equivalent, to a patient with lung fibrosis. Claim 2 adds oral, parenteral, and rectal administration routes.

The patent does not claim the nintedanib molecule broadly, a specific dosage, a particular formulation, or a manufacturing process. Its commercial value is concentrated in the therapeutic-use field. The patent's nominal 20-year term ran from its earliest effective nonprovisional filing date and reached its ordinary expiration in 2025, subject to any patent-term adjustment reflected in USPTO records.

What drug does U.S. Patent 7,989,474 protect?

The claimed active ingredient is nintedanib. The chemical name in claim 1 identifies the molecule as:

"(Z)-3-(1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene)-6-methoxycarbonyl-2-indolinone."

Nintedanib is a small-molecule tyrosine kinase inhibitor marketed in the United States as Ofev by Boehringer Ingelheim Pharmaceuticals, Inc. The FDA approved Ofev in 2014 for idiopathic pulmonary fibrosis. Later approvals expanded its use to other progressive fibrosing interstitial lung diseases and systemic sclerosis-associated interstitial lung disease.[2]

Claim construction summary

Claim element	Scope
Patient	A patient in need of treatment
Disease	Lung fibrosis
Active agent	Nintedanib or a listed tautomer, stereoisomer, or physiologically acceptable salt
Dosage requirement	An effective amount
Dosage form	Pharmaceutical composition
Claim type	Method of medical treatment
Administration route in claim 1	Not expressly limited
Administration route in claim 2	Oral, parenteral, or rectal

Claim 1 uses "comprising," which generally makes the composition limitation open-ended. A product containing nintedanib together with excipients, stabilizers, coatings, or other pharmaceutical ingredients can fall within the composition language if the claimed therapeutic method is otherwise satisfied.

What is the legal scope of claim 1?

Claim 1 has five operative limitations:

Treatment must involve a patient.
The patient must have, or be in need of treatment for, lung fibrosis.
The administered product must be a pharmaceutical composition.
The composition must contain nintedanib or one of the listed chemical alternatives.
The amount administered must be effective for treatment.

The claim is broad across the lung-fibrosis disease category. It does not limit treatment to idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonitis, systemic sclerosis-associated interstitial lung disease, or another named subtype. A court would analyze the meaning of "lung fibrosis" using the patent specification, prosecution history, and ordinary technical meaning.

The claim also does not specify:

A dose or dosing frequency
A treatment duration
A patient age
Disease severity
A biomarker
A combination therapy
A particular capsule or tablet formulation
A particular salt
A specific pharmacokinetic profile
A requirement that lung function improve
A requirement that fibrosis be idiopathic

The absence of those limitations increases the claim's potential breadth but also creates potential validity and infringement issues. The claim must still satisfy written description, enablement, novelty, nonobviousness, definiteness, and other requirements under the Patent Act.[3]

How do the chemical alternatives affect coverage?

The phrase "or a tautomer, stereoisomer or physiologically acceptable salt thereof" expands the claim beyond one neutral chemical representation of nintedanib.

The practical coverage is as follows:

Chemical form	Potential coverage
Nintedanib free base	Expressly covered
Pharmaceutically acceptable salt	Expressly covered
Tautomer	Expressly covered
Stereoisomer	Expressly covered
Solvate or hydrate	Potentially covered only if it falls within the claimed salt, tautomer, stereoisomer, or composition construction
Prodrug	Not automatically covered
Different active compound	Not covered merely because it has similar activity

A generic applicant cannot avoid the claim simply by using a pharmaceutically acceptable salt if that salt falls within the claim. A different prodrug or chemically modified derivative would require a separate infringement analysis.

What does claim 2 add?

Claim 2 specifies that the composition may be administered orally, parenterally, or rectally. Its principal commercial relevance is oral administration because Ofev is supplied as oral soft capsules.

Claim 2 is narrower than claim 1. It may provide an additional infringement route for oral nintedanib products, but it does not materially narrow the commercial product category for ordinary Ofev-style capsules. Claim 2 does not require a capsule, a softgel, a particular excipient, or a particular release profile.

Parenteral administration includes routes such as intravenous, intramuscular, or subcutaneous delivery depending on the construction of the term and the specification. Rectal administration is expressly included but has little apparent relevance to the marketed Ofev product.

What patents protect Ofev and nintedanib?

U.S. Patent 7,989,474 is a use patent. It should be distinguished from patents that may protect the underlying chemical compound, pharmaceutical compositions, formulations, salts, dosing regimens, or other clinical uses.

Patent category	Relevance to nintedanib
Compound patent	Can protect nintedanib itself across therapeutic uses
Lung-fibrosis use patent	Protects use of nintedanib for lung fibrosis
Formulation patent	Can protect capsule composition, excipient system, dissolution, or stability
Method-of-use patent	Can protect a particular disease, patient population, regimen, or combination
Manufacturing patent	Can restrict a process used to make nintedanib or an intermediate
Regulatory exclusivity	Can delay FDA approval independently of patent expiration

Patent 7,989,474 does not, based on the supplied claims, claim the chemical compound in the abstract. It also does not claim a specific manufacturing route. A competitor could therefore face separate barriers even if it designs around this patent's lung-fibrosis method claims.

What is the expiration date of U.S. Patent 7,989,474?

The ordinary patent term is measured from the earliest effective nonprovisional filing date, not simply from the issue date.[3] The patent's priority history places its nominal term in 2025. The practical expiration date must be determined from the USPTO patent record, including any patent-term adjustment or terminal disclaimer.

Event	Date or status
Patent	U.S. 7,989,474
Issue date	August 2, 2011
Nominal term endpoint	2025, based on the earliest effective filing date
Patent-term extension	Must be checked separately under 35 U.S.C. § 156
Patent-term adjustment	Must be checked in the USPTO record
Post-expiration relevance	Patent rights generally cease at expiration, subject to limited statutory exceptions

A patent-term extension based on regulatory review is distinct from patent-term adjustment for USPTO examination delay. The FDA's regulatory approval history alone does not establish that this particular patent received a patent-term extension.

What is the Orange Book status of U.S. Patent 7,989,474?

The Orange Book lists patents submitted by a new drug application holder for an approved drug. For a small-molecule product such as Ofev, an ANDA applicant must address listed patents through a Paragraph I, II, III, or IV certification under the Hatch-Waxman framework.[4]

The relevant commercial questions are:

Whether 7,989,474 was listed for Ofev
Which FDA use code was assigned
Whether the listed use corresponds to the proposed generic labeling
Whether the patent was expired, delisted, or still actionable when an ANDA was filed
Whether a Paragraph IV notice triggered litigation and a 30-month stay

A use patent does not necessarily block every generic launch. An ANDA applicant may use a section viii statement to carve out a patented indication when the proposed labeling omits the protected use. That strategy is less effective when the patented use is central to the reference product's labeling or when the FDA requires wording that overlaps the patented method.[4]

When does Ofev lose exclusivity?

Ofev's exclusivity has several components:

Exclusivity type	Relevance
New chemical entity exclusivity	Initially delayed ANDA submission for the active ingredient
Orphan-drug exclusivity	Relevant to the idiopathic pulmonary fibrosis indication
Patent exclusivity	Depends on compound, use, formulation, and other listed patents
Pediatric exclusivity	Could add six months if awarded
Regulatory exclusivity for later indications	Depends on the approval pathway and indication

The 2014 FDA approval for idiopathic pulmonary fibrosis triggered orphan-drug exclusivity for that indication. The later FDA approvals for progressive fibrosing interstitial lung disease and systemic sclerosis-associated interstitial lung disease had separate regulatory significance but did not automatically revive an expired patent.[2]

Patent 7,989,474 reached its nominal term endpoint in 2025. A generic applicant's practical launch date can still depend on other unexpired Ofev patents, FDA exclusivity, litigation settlements, and the proposed label.

What Paragraph IV risks exist for a nintedanib generic?

A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For this patent, likely challenge theories would focus on the following issues:

Claim breadth and written description

The claim covers lung fibrosis generally, while the patent's experimental disclosure may be assessed for the breadth of that disease category. A challenger could argue that the specification does not adequately support every form of lung fibrosis covered by the claim.

Enablement

The challenger could argue that practicing the full scope of treating lung fibrosis with nintedanib requires undue experimentation. The strength of that argument depends on the amount of clinical and mechanistic disclosure in the patent and the predictability of the field at the relevant filing date.

Obviousness

Prior art involving nintedanib, related indolinones, tyrosine kinase inhibition, angiogenesis, pulmonary fibrosis, or other fibrotic diseases could be used to argue that the claimed therapeutic use was obvious.

Anticipation

A single prior-art reference would need to disclose all claim limitations, including use of nintedanib for lung fibrosis. A compound reference without the lung-fibrosis treatment disclosure would not necessarily anticipate claim 1.

Infringement and label carve-out

A generic product may avoid direct method infringement if its FDA-approved label omits the patented indication. Risk remains if the manufacturer induces use for the patented indication through labeling, promotional activity, distribution practices, or other evidence.

Does nintedanib face biosimilar risk?

No. Nintedanib is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.

The principal competitive risks are therefore:

Generic nintedanib capsules
Authorized generic distribution
Paragraph IV litigation
Section viii labeling carve-outs
Alternative antifibrotic therapies
Formulation or salt-based patent disputes

What formulation patents may affect generic entry?

The supplied claims do not contain formulation-specific limitations. They require a "pharmaceutical composition" but do not define:

Capsule shell composition
Excipient identity
Particle size
Dissolution profile
Release rate
Stability specification
Solid-state form
Manufacturing temperature
Packaging system

A generic manufacturer could still face separate formulation patents if the proposed product uses the same protected excipient system, capsule technology, polymorph, or manufacturing process. Those patents must be assessed separately from U.S. 7,989,474.

The distinction is commercially important. Designing around a formulation patent may be possible through excipient substitution or a different manufacturing process. Designing around a broad therapeutic-use patent is more difficult when the generic label includes the patented indication.

What litigation and settlement issues affect nintedanib?

The relevant litigation record is the ANDA litigation docket tied to each Paragraph IV notice. A complete assessment must distinguish:

District-court litigation under 35 U.S.C. § 271(e)(2)
Federal Circuit appeals
FDA 30-month stays
Consent judgments
Patent expiry dates
Settlement agreements with authorized launch dates
Covenants not to sue
At-risk launches

A settlement may permit a generic launch before the last patent expires without invalidating the patent. The agreement may also contain restrictions on the product label, supply source, launch date, or marketing status. Patent expiry alone does not establish that a generic launched immediately, and litigation dismissal alone does not establish freedom to market.

How strong is the patent estate for lung-fibrosis treatment?

The strength of U.S. 7,989,474 is moderate as a historical blocking patent and limited as a current standalone barrier after its nominal 2025 term.

Factor	Assessment
Claim category	Broad therapeutic-use claim
Chemical specificity	High; directed to nintedanib and defined equivalents
Disease specificity	Broad within lung fibrosis
Dose limitation	None
Route limitation	None in claim 1
Formulation limitation	Minimal
Design-around difficulty	High if the patented indication is labeled; lower with a lawful carve-out
Current term value	Dependent on verified PTA, PTE, and related patents
Biosimilar relevance	None
Generic pathway	ANDA

The claim's strongest feature is the combination of a specifically identified active ingredient with a broad disease category. Its principal weakness is that it is a use claim subject to prior-art, enablement, written-description, and label-carve-out challenges.

What generic launch scenarios exist?

Full-label launch

A generic applicant includes lung-fibrosis indications in its labeling. This creates the highest exposure to a listed method-of-use patent and related induced-infringement claims.

Carved-label launch

The applicant removes the patented indication under section viii. The commercial opportunity depends on whether the remaining indications are substantial and whether the FDA accepts the carve-out.

Post-expiry launch

The applicant waits until the relevant patent and regulatory exclusivities expire. This reduces litigation risk but may surrender first-filer advantages.

At-risk launch

The applicant launches before final resolution of litigation. This can accelerate market entry but exposes the company to damages, injunction risk, and potential disruption of supply.

How does nintedanib compare with competing antifibrotic drugs?

Drug	Active ingredient	Drug type	Primary pulmonary-fibrosis use	Competitive pathway
Ofev	Nintedanib	Small-molecule kinase inhibitor	IPF and selected progressive fibrosing ILDs	ANDA generic
Esbriet	Pirfenidone	Small molecule	Idiopathic pulmonary fibrosis	ANDA generic
Other ILD therapies	Varies	Small molecules or biologics	Disease-specific or investigational	Product-specific

Nintedanib and pirfenidone compete clinically in idiopathic pulmonary fibrosis. Their patent estates differ because nintedanib has molecule, use, formulation, and dosing considerations, while pirfenidone has a separate compound and indication history. Neither product creates biosimilar competition.

Key Takeaways

U.S. Patent 7,989,474 is a nintedanib method-of-treatment patent.
Claim 1 covers administering nintedanib, defined chemical equivalents, or acceptable salts for lung fibrosis.
Claim 2 expressly covers oral, parenteral, and rectal administration.
The claims do not require a specific dose, formulation, capsule, regimen, or lung-fibrosis subtype.
The patent is not a compound, formulation, or manufacturing patent based on the supplied claims.
Its nominal patent term reached 2025, subject to USPTO-recorded term adjustments or extensions.
Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
Section viii label carving may reduce infringement exposure where the patented indication can lawfully be omitted.
Other Ofev patents and regulatory exclusivities may remain commercially relevant even after this patent expires.
A complete launch assessment requires review of Orange Book listings, FDA use codes, Paragraph IV notices, ANDA litigation, settlements, and related Ofev patents.

FAQs

Is U.S. Patent 7,989,474 a composition-of-matter patent?

No. The supplied claims are method-of-treatment claims. They require administering a pharmaceutical composition containing nintedanib or a specified chemical equivalent for lung fibrosis.

Does changing the nintedanib dose avoid the patent?

Not necessarily. Claim 1 contains no numerical dose limitation. A different dose may remain within the claim if it is an effective amount used to treat lung fibrosis.

Does using a nintedanib salt avoid infringement?

No. Claim 1 expressly includes physiologically acceptable salts of nintedanib.

Can a generic sell nintedanib for non-patented indications?

Potentially. A generic may seek a section viii carve-out if the FDA-approved labeling can omit the patented indication and the resulting marketing conduct does not induce use of that indication.

Is Ofev protected by orphan-drug exclusivity after the lung-fibrosis patent expires?

Orphan-drug exclusivity and patent protection are separate rights. Patent expiry does not itself terminate orphan-drug exclusivity, and orphan-drug exclusivity does not extend the patent term.

References

U.S. Patent No. 7,989,474. (2011). United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2014). Ofev (nintedanib) prescribing information.
35 U.S.C. §§ 154, 156, 271(e)(2).
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 37 423	Aug 16, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003255413	⤷ Start Trial
Canada	2495350	⤷ Start Trial
Cyprus	1116093	⤷ Start Trial
Germany	10237423	⤷ Start Trial
Denmark	1530466	⤷ Start Trial
European Patent Office	1530466	⤷ Start Trial
European Patent Office	2281561	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,989,474

Summary for Patent: 7,989,474